About the job
About Us:
Cogent Biosciences is a pioneering biotechnology firm committed to innovating precision therapies aimed at addressing significant medical needs. Our flagship treatment, bezuclastinib, is engineered to selectively inhibit exon 17 mutations in the KIT receptor tyrosine kinase, which includes the KIT D816V mutation. This mutation plays a critical role in conditions such as Systemic Mastocytosis—a rare and severe disorder—and is also implicated in gastrointestinal stromal tumors (GIST), a cancer type that heavily relies on oncogenic KIT signaling. Bezuclastinib has demonstrated encouraging initial results across three pivotal trials: APEX for AdvSM, SUMMIT for NonAdvSM, and PEAK for GIST, showcasing a favorable safety profile among over 600 patients in both single-agent and combination therapies.
Position Overview:
The Director of Patient and Community Education will play a vital role in leading Cogent's Patient Advocacy & Engagement team as we prepare for the upcoming commercial introduction of bezuclastinib in Non-Advanced Systemic Mastocytosis, Advanced Systemic Mastocytosis, and Gastrointestinal Stromal Tumors. This strategic leader will oversee a dedicated Patient Educator Team, driving the development and implementation of our patient education and engagement strategy for Systemic Mastocytosis and GIST.
This position extends beyond mere team management; it will catalyze patient empowerment, foster trust, and enhance health outcomes. The Director will build and continuously refine a Patient Educator organization that provides compliant, empathetic, and clinically reliable patient education through both in-person and digital channels. This leader will also act as a vital link between patients and cross-functional teams, ensuring that patient insights significantly influence our organizational strategies.